Compositions and methods of use of targeting peptides against placenta and adipose tissues
View Patent ↗The present invention concerns compositions comprising and methods of identification and use of targeting peptides for placenta or adipose tissue. In certain embodiments, the targeting peptides comprise part or all of SEQ ID NO:5-11, SEQ ID NO:13-22 or SEQ ID NO:144. The peptides may be attached to various therapeutic agents for targeted delivery. Adipose-targeting peptides may be used in methods for weight control, inducing weight loss and treating lipodystrophy syndrome. Adipose-targeting may also be accomplished using other binding moieties selectively targeted to adipose receptors, such as a prohibition receptor protein complex. Placenta-targeting peptides may be used to interfere with pregnancy, induce labor and/or for targeted delivery of therapeutic agents to placenta and/or fetus. In other embodiments, receptors identified by binding to placenta-targeting peptides may be used to screen compounds for potential teratogenicity. An exemplary placental receptor is FcRn/β 2 M, and compounds that bind to FcRn/β 2 M are potential teratogens.
1. A method of treating obesity comprising:
a) obtaining an isolated peptide of 100 amino acids or less in size comprising at least the contiguous amino acids of SEQ ID NO:19;
b) attaching the peptide to a therapeutic agent to form a complex;
c) administering the complex to a subject; and
d) inducing weight loss in the subject.
2. The method of claim 1 , wherein the subject is a human, a mouse, a dog, a cat, a rat, a sheep, a horse, a cow, a goat or a pig.
3. The method of claim 1 , wherein the isolated peptide comprises the amino acid sequence of SEQ ID NO:22.
4. The method of claim 1 , wherein said therapeutic agent is a drug, a chemotherapeutic agent, a radioisotope, a pro-apoptosis agent, an anti-angiogenic agent, a hormone, a cytokine, a cytotoxic agent, a cytocidal agent, a cytostatic agent, a peptide, a protein, an antibiotic, an antibody, a Fab fragment of an antibody, a hormone antagonist, a nucleic acid or an antigen.
5. The method of claim 4 , wherein said therapeutic agent is a pro-apoptosis agent selected from the group consisting of gramicidin, magainin, mellitin, defensin, cecropin, (KLAKLAK) 2 (SEQ ID NO:1), (KLAKKLA) 2 (SEQ ID NO:2), (KAAKKAA) 2 (SEQ ID NO:3) and (KLGKKLG) 2 (SEQ ID NO:4).
6. The method of claim 5 , wherein the pro-apoptosis agent is (KLAKLAK) 2 (SEQ ID NO:1).
7. The method of claim 4 , wherein the therapeutic agent is an anti-angiogenic agent selected from the group consisting of thrombospondin, angiostatin5, pigment epithelium-derived factor, angiotensin, laminin peptides, fibronectin peptides, plasminogen activator inhibitors, tissue metalloproteinase inhibitors, interferons, interleukin 12, platelet factor 4, IP-10, Gro-B, thrombospondin, 2-methoxyoestradiol, proliferin-related protein, carboxiamidotriazole, CM101, Marimastat, pentosan polysulphate, angiopoietin 2 (Regeneron), interferon-alpha, herbimycin A, PNU145156E, 16K prolactin fragment, Linomide, thalidomide, pentoxifylline, genistein, TNP-470, endostatin, paclitaxel, Docetaxel, polyamines, a proteasome inhibitor, a kinase inhibitor, a signaling peptide, accutin, cidofovir, vincristine, bleomycin, AGM-1470, platelet factor 4 and minocycline.
8. The method of claim 4 , wherein the therapeutic agent is a cytokine selected from the group consisting of interleukin 1 (IL-1), IL-2, IL-5, IL-10, IL-11, IL-12, IL-18, interferon-γ (IF-γ), IF-α, IF-β, tumor necrosis factor-α (TNF-α), or GM-CSF (granulocyte macrophage colony stimulating factor).
9. The method of claim 1 , wherein said complex is administered intravenously or subcutaneously.
10. The method of claim 1 , wherein said complex is macromolecular complex.
11. The method of claim 10 , wherein said macromolecular complex is a virus, a bacteriophage, a bacterium, a liposome, a microparticle, a magnetic bead, a yeast cell, a mammalian cell, a cell or a microdevice.
12. The method of claim 10 , wherein said macromolecular complex is a eukaryotic expression vector.
13. The method of claim 12 , wherein said vector is a gene therapy vector.